Palvella Therapeutics PVLA Cash Flow Statement (2013-2026)

NASDAQ PVLA
$157.24 +1.77 (+1.14%)
As of: Sep 4, 2026 · 3:59 PM EDT
Reported Financials

Palvella Therapeutics Quarterly Cash Flow Statement

Periods 53 quarters
Latest Jun 2026

Palvella Therapeutics reported cash from operations of -$12.81M and free cash flow of -$12.81M for the quarter ended Jun 2026, down 137.1% year over year. This cash flow statement covers 53 quarters of results from Jun 2013 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Jun2013 Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-19.01M-11.01M-7.46M-12.20M-11.93M-11.17M-15.15M2.55M-11.26M13.84M-2.54M-4.17M-6.78M-0.29M-8.19M-9.47M-11.35M-4.02M-15.77M-21.87M
Share-based CompensationStock Comp.
1.37M1.32M1.18M1.30M0.97M0.95M0.88M1.05M0.97M-2.29M0.15M0.22M0.33M0.27M2.51M2.70M20.50M2.08M51.60M55.20M
Asset Writedowns and ImpairmentWritedown
14.89M-0.98M
Cash from OperationsCash from Ops.
-14.48M-10.94M-22.64M-15.58M-8.78M-12.93M-11.00M-13.43M-9.72M20.45M-1.10M-1.60M-2.74M-5.39M-6.80M-5.40M-7.90M-4.91M-10.90M-12.81M
Depreciation, Depletion & Amortization
Amortizatization of IntangiblesAmort. of Intangibles
0.01M0.32M
Amortization of Deferred ChargesAmort. Deferred Charges
Depreciation & Amortization (CF)Dep. & Amort.
0.61M0.84M0.58M0.77M0.57M0.60M0.76M0.74M-0.20M
Change in Working Capital
Change in ReceivablesChange Receivables
-0.36M-0.03M
Change in Account PayablesChange Payables
0.09M0.42M1.69M0.04M1.12M0.12M-1.14M1.16M0.85M1.35M
Change in Accured ExpensesChange Accured Exp.
0.29M0.74M0.38M-0.36M-2.91M0.52M0.80M0.29M-0.90M1.49M
Change in TaxesChange Taxes
Other Working Capital ChangesOther WC Changes
-0.06M19.65M7.29M0.45M-0.61M18.89M15.52M3.96M-2.19M-1.86M
Investing Activities
Capital ExpendituresCapex
0.35M0.34M0.39M0.63M0.03M-0.01M0.05M0.07M0.07M-0.01M
Sales of Property, Plant and EquipmentPP&E (Sale)
0.14M
Change in Acquisitions & DivestmentsChange Acquisitions
4.85M17.05M6.30M13.49M5.40M5.11M11.00M9.00M
Cash from Investing ActivitiesCash from Investing
-0.35M-0.34M-16.95M-10.87M5.47M1.11M11.90M-1.37M-1.98M3.45M9.00M2.18M0.14M-55.44M-7.03M
Financing Activities
Other financing activitiesOther financing
0.09M0.02M0.09M0.05M-0.05M60.00M0.07M0.35M0.24M0.10M14.25M
Cash from Financing ActivitiesCash from Financing
21.92M4.90M6.56M0.28M0.28M0.09M19.78M-14.78M9.89M2.41M74.78M-1.20M0.35M0.24M-0.05M214.73M1.28M
Change in Capital Stock
Net Shares Issued and RepurchasedNet Shares Issued
3.18M3.08M3.73M1.18M0.89M1.36M0.45M
Net Equity Issued and RepurchasedNet Equity Issued
21.35M4.67M6.47M0.17M0.28M19.73M230.00M
Additional items
Exchange Rate EffectFX Effect
-1.13M-0.90M-0.99M-3.32M-2.81M1.95M0.20M0.21M-0.34M-0.07M0.00M-0.01M-0.11M0.77M-0.61M-0.01M0.01M
Change in Cash
5.96M-7.29M-34.03M-29.48M-5.83M-9.79M1.11M5.20M-12.04M-2.96M-1.10M8.29M-0.33M69.39M-7.98M-5.19M-6.87M-5.58M148.41M-18.59M
Free Cash FlowFCF
-14.83M-11.29M-23.03M-16.21M-8.81M-12.92M-11.04M-13.50M-9.79M20.46M-1.10M-1.60M-2.74M-5.39M-6.80M-5.40M-7.90M-4.91M-10.90M-12.81M
Net Cash FlowNCF
7.08M-6.38M-33.03M-26.16M-3.03M-11.73M0.91M4.98M-11.71M9.12M7.90M10.46M-0.19M69.39M-8.00M-5.05M-7.66M-4.96M148.39M-18.56M